Enhanced activation of SHH signaling has been linked to the progression of breast and pancreatic cancers [27, 28], and selective HHAT chemical probes [22] and several inhibitors have been developed as potential therapeutic agents [24, 28]. This evidence concerns the gene SHH and familial pancreatic carcinoma.